- Home
- OTLK vs PED Comparison
OTLK vs PED Comparison
Compare OTLK & PED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- PED
- Stock Information
- Founded
- OTLK 2010
- PED N/A
- Country
- OTLK United States
- PED United States
- Employees
- OTLK N/A
- PED N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- PED Oil & Gas Production
- Sector
- OTLK Health Care
- PED Energy
- Exchange
- OTLK Nasdaq
- PED Nasdaq
- Market Cap
- OTLK 48.3M
- PED 48.8M
- IPO Year
- OTLK 2016
- PED N/A
- Fundamental
- Price
- OTLK $1.71
- PED $0.72
- Analyst Decision
- OTLK Strong Buy
- PED Strong Buy
- Analyst Count
- OTLK 5
- PED 2
- Target Price
- OTLK $9.60
- PED $1.63
- AVG Volume (30 Days)
- OTLK 823.9K
- PED 486.8K
- Earning Date
- OTLK 08-13-2025
- PED 08-13-2025
- Dividend Yield
- OTLK N/A
- PED N/A
- EPS Growth
- OTLK N/A
- PED 2248.88
- EPS
- OTLK 0.83
- PED 0.19
- Revenue
- OTLK N/A
- PED $40,173,000.00
- Revenue This Year
- OTLK N/A
- PED N/A
- Revenue Next Year
- OTLK $379.84
- PED $5.99
- P/E Ratio
- OTLK $2.06
- PED $3.78
- Revenue Growth
- OTLK N/A
- PED 30.70
- 52 Week Low
- OTLK $0.87
- PED $0.47
- 52 Week High
- OTLK $9.25
- PED $1.10
- Technical
- Relative Strength Index (RSI)
- OTLK 46.49
- PED 59.82
- Support Level
- OTLK $1.65
- PED $0.66
- Resistance Level
- OTLK $1.97
- PED $0.78
- Average True Range (ATR)
- OTLK 0.12
- PED 0.04
- MACD
- OTLK -0.03
- PED 0.01
- Stochastic Oscillator
- OTLK 10.94
- PED 52.32
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.